Patients treated with ligelizumab achieve freedom from signs and symptoms of chronic spontaneous urticaria regardless of the angioedema status at baseline
K. Sitz, W. Soong, J. A. Bernstein, M. Maurer, A. Giménez-Arnau, E. Hua, C. M. Tafur, T. Severin
Complete freedom from chronic spontaneous urticaria signs and symptoms is associated with sleep and dermatology quality-of-life improvements: Data from the phase 2b ligelizumab study
J. A. Bernstein, A. Giménez-Arnau, M. Hide, M. Maurer, K. Sitz, G. Sussman, C-E. Ortmann, M-M. Balp, C. M. Tafur, T. Severin
Remibrutinib (LOU064) for Chronic Spontaneous Urticaria: Time to Complete Urticaria Control
M. Maurer, P. Yamauchi, H. Kanavy , A. Giménez Arnau , J. Reed, P. Staubach, K. Lheritier , P.
Walsh, I. Nikolaev, S. Haemmerle, M. Lebwohl
2021
Ligelizumab further reduced sleep impairment in patients with chronic spontaneous urticaria previously treated with omalizumab
M. Maurer, K. Sitz, G. Sussman, M. Metz, M. Hide, A.Giménez-Arnau, N. Barbier, E. Hua, R. Janocha, M.M. Balp, T. Severin
High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the Phase 2b core study
J.A. Bernstein, M. Maurer, A. Giménez-Arnau, W. Soong, K. Sitz, E. Hua, N. Barbier, A. Barve, T. Severin, R. Janocha
2020
No publication submitted this year
2019
Ligelizumab achieves sustained symptom control up to 1 year in the majority of patients with chronic spontaneous urticaria: Results of the 1-year extension study of the Phase 2b trial
J. A. Bernstein, D. Baker, M. Maurer, A. Giménez-Arnau, G. Sussman, A. Barve, E. Hua, T. Severin, R. Janocha
